- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07898774
A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients (PRESERVE)
A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis
To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients
연구 개요
상태
정황
개입 / 치료
상세 설명
The PRESERVE study is a Phase 3b, multicenter, single-arm, open-label clinical trial designed to explore the efficacy and safety of pegcetacoplan in preventing or delaying the recurrence of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) following kidney transplantation. Recurrence of these diseases after transplantation is common and can lead to graft dysfunction and loss. Pegcetacoplan is a complement C3/C3b inhibitor that has demonstrated activity in patients with native kidney disease and recurrent disease after transplantation. The study aims to assess whether initiating pegcetacoplan at the time of kidney transplantation, before recurrence occurs, may delay the recurrence and support long-term graft outcomes. Participants will receive pegcetacoplan in addition to standard post-transplant care and will be followed to evaluate disease recurrence, kidney function, graft outcomes, safety, and tolerability.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Study Physician
- 전화번호: +46 86972000
- 이메일: medical.info@sobi.com
연구 장소
-
-
Lower Saxony
-
Hanover, Lower Saxony, 독일, 30625
- Medizinische Hochschule Hannover
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, 독일, 50937
- Universitaetsklinikum Koeln
-
Essen, North Rhine-Westphalia, 독일, 45147
- Universitaetsklinikum Essen
-
-
-
-
Pernambuco
-
Recife, Pernambuco, 브라질, 52010-010
- Real Hospital Português
-
-
São Paulo
-
Botucatu, São Paulo, 브라질, 18618-970
- UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
-
São Paulo, São Paulo, 브라질, 05403-000
- Hospital das Clinicas da Faculdade de Medicina da USP - HCFMUSP
-
-
-
-
-
Riyadh, 사우디 아라비아, 11211
- King Faisal Specialist Hospital & Research Center
-
-
-
-
-
Lausanne, 스위스, 1011
- Centre Hospitalier Universitaire Vaudois (CHUV)
-
-
-
-
Barcelona
-
Barcelona, Barcelona, 스페인, 8035
- Hospital Universitari Vall d'Hebron - VHIR
-
-
La Coruña
-
A Coruña, La Coruña, 스페인, 15006
- Complejo Hospitalario Universitario A Coruña
-
-
Madrid
-
Madrid, Madrid, 스페인, 28041
- Hospital Universitario 12 de Octubre
-
-
Málaga
-
Málaga, Málaga, 스페인, 29010
- Hospital Regional Universitario de Malaga
-
-
Vizcaya
-
Barakaldo, Vizcaya, 스페인, 48903
- Hospital de Cruces
-
-
-
-
Greater London
-
London, Greater London, 영국, NW3 2QG
- Royal Free Hospital
-
London, Greater London, 영국, W12 0HS
- Hammersmith Hospital
-
-
Greater Manchester
-
Manchester, Greater Manchester, 영국, M13 9WL
- Manchester Royal Infirmary
-
-
Tyne & Wear
-
Newcastle upon Tyne, Tyne & Wear, 영국, NE7 7DN
- Freeman Hospital
-
-
-
-
Bari
-
Bari, Bari, 이탈리아, 70124
- Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
-
-
Bergamo
-
Bergamo, Bergamo, 이탈리아, 24127
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
-
-
Roma
-
Roma, Roma, 이탈리아, 165
- Ospedale Pediatrico Bambino Gesù
-
Roma, Roma, 이탈리아, 168
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
-
-
-
Alberta
-
Edmonton, Alberta, 캐나다, T6G 2R7
- University of Alberta - Faculty of Medicine & Dentistry
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V6Z 1Y6
- St. Paul's Hospital
-
-
Ontario
-
London, Ontario, 캐나다, N6A 5A5
- London Health Sciences Centre (LHSC) - University Hospital
-
Toronto, Ontario, 캐나다, M5G 2C4
- Toronto General Hospital
-
-
Quebec
-
Montreal, Quebec, 캐나다, H4A 3J1
- McGill University Health Centre Research Institute
-
-
-
-
Bas Rhin
-
Strasbourg, Bas Rhin, 프랑스, 67091
- CHU Strasbourg - Nouvel Hôpital Civil
-
-
Haute Garonne
-
Toulouse, Haute Garonne, 프랑스, 31059
- Hopital Rangueil
-
-
Herault
-
Montpellier, Herault, 프랑스, 34000
- Hopital Lapeyronie pt
-
-
Nord
-
Lille, Nord, 프랑스, 59037
- Hopital Claude Huriez - CHU Lille
-
-
Paris
-
Paris, Paris, 프랑스, 75015
- Hôpital Necker - Enfants Malades
-
-
Rhone
-
Lyon, Rhone, 프랑스, 69437
- Hopital Edouard Herriot - CHU Lyon
-
-
-
-
-
Helsinki, 핀란드, 290
- Helsinki University Central Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female patients with a diagnosis of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) who are planning to undergo kidney transplantation because of the disease.
- Have a high risk of disease recurrence following kidney transplantation, based on either having a previous kidney allograft loss due to recurrence of C3G or primary IC-MPGN, or assessed as having a high risk by the investigator based on other clinical information.
- Is fully vaccinated and up to date with their vaccinations against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B, in accordance with local guidelines, at the time of initiating pegcetacoplan.
Exclusion Criteria:
- A known secondary cause for MPGN, including but not limited to monoclonal gammopathy of clinical significance, hepatitis B, hepatitis C, or autoimmune cryoglobulinemia.
- History of invasive meningococcal disease.
- History of malignancy, except for the following: cured basal or squamous cell skin cancer, curatively treated in situ disease, or currently malignancy-free and has been off-treatment for the malignancy for at least 5 years.
- Hypersensitivity to pegcetacoplan or any of its excipients.
- Known or suspected hereditary fructose intolerance.
- Any other medical condition which, in the opinion of the Investigator, makes the participant unsuitable for inclusion.
- Use of a complement inhibitor for the treatment of C3G or primary IC-MPGN within 1 month prior to the scheduled kidney transplantation surgery.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Pegcetacoplan
Pegcetacoplan, a complement C3/C3b inhibitor, administered according to the study protocol in kidney transplant recipients with high risk of recurring C3G or primary IC-MPGN |
Dose amount based on age and weight Subcutaneous infusion twice-a-week. Adult participants aged 18 years or older at enrolment: 1080 mg Adolescent participants aged 12 to 17 years at enrolment:
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Occurrence of Clinically Significant Recurrent Disease
기간: Within 2 years after kidney transplantation
|
Histological evidence of recurrent disease based on the histopathological assessment of the kidney biopsy |
Within 2 years after kidney transplantation
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to Onset of Clinically Significant Disease Recurrence
기간: Up to 2 years after kidney transplantation
|
To explore the impact of pegcetacoplan on time to clinically significant recurrence of C3G or primary IC-MPGN after kidney transplantation |
Up to 2 years after kidney transplantation
|
공동 작업자 및 조사자
협력자
수사관
- 연구 책임자: Study Physician, Swedish Orphan Biovitrum AB (publ)
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- Sobi.PEGCET-404
- 2026-526392-39-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers may request access to patient level data and related study documents.
All requests are evaluated by a cross functional panel of experts within Sobi. Patient level data will be anonymized and study documents, if applicable, will be redacted to protect the privacy of trial participants.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .